Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.…
Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock
Disc Medicine (NASDAQ: IRON) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 173 employees.
The shares were at 75.14 USD on 20 November 2026, down 10.1% over 52 weeks. Its 52-week range is 40.00 USD to 99.50 USD: the price is 24.5% below the high and 87.8% above the low.
Its market capitalisation is 3.42B USD.
Disc Medicine reports return on equity of -28.7% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 621.73M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 13 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 127.69 USD is 69.9% above the current price. The next earnings report is expected on 25 February 2027.